for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aravive Inc

ARAV.OQ

Latest Trade

5.95USD

Change

0.15(+2.59%)

Volume

20,031

Today's Range

5.75

 - 

6.01

52 Week Range

3.41

 - 

14.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.80
Open
5.79
Volume
20,031
3M AVG Volume
3.11
Today's High
6.01
Today's Low
5.75
52 Week High
14.94
52 Week Low
3.41
Shares Out (MIL)
16.09
Market Cap (MIL)
93.31
Forward P/E
-2.61
Dividend (Yield %)
--

Next Event

Q4 2020 Aravive Inc Earnings Release

Latest Developments

More

Aravive Inc - Received Guidance From U.S FDA On Phase 3 Trial Design For Avb-500 In Platinum Resistant Ovarian Cancer

Aravive Inc Says Entered Into Collaboration And License Agreement With 3D Medicines Inc On November 6

Aravive Reports Third Quarter 2020 Financial Results And Provides Corporate Updates

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aravive Inc

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.

Industry

Biotechnology & Drugs

Contact Info

RIVER OAKS TOWER

3730 KIRBY DRIVE, SUITE 1200

HOUSTON, TX

77098

United States

+1.936.3551910

https://aravive.com/

Executive Leadership

Fredric N. Eshelman

Independent Chairman of the Board

Gail F. McIntyre

President, Chief Executive Officer, Director

Vinay Shah

Chief Financial Officer

Reshma Rangwala

Chief Medical Officer

Michael W. Rogers

Director

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-14.460

2019

-1.570

2020(E)

-2.220
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-54.77
Return on Equity (TTM)
-49.79

Latest News

Latest News

BRIEF-Aravive Says Co Added To Russell 2000 And Russell 3000 Indexes

* ARAVIVE ADDED TO THE RUSSELL 2000® AND RUSSELL 3000® INDEXES Source text for Eikon: Further company coverage:

BRIEF-Aravive Files For Offer And Resale Of Up To 931,098 Shares By Selling Stockholder - SEC Filing

* ARAVIVE INC FILES FOR OFFER AND RESALE OF UP TO 931,098 SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: https://bit.ly/2Vqye36 Further company coverage:

BRIEF-Aravive Says Rekha Hemrajani Has Resigned As CEO And As A Director

* ARAVIVE INC - REKHA HEMRAJANI HAS RESIGNED AS COMPANY'S CHIEF EXECUTIVE OFFICER AND AS A DIRECTOR

BRIEF-Aravive - Avb-500 Improves Anti-Tumor Effects When Combined With Anti-Angiogenic Bevacizumab Or Parp Inhibitor Olaparib For Uterine Cancer

* ARAVIVE ANNOUNCES AVB-500 IMPROVES ANTI-TUMOR EFFECTS WHEN COMBINED WITH ANTI-ANGIOGENIC BEVACIZUMAB OR PARP INHIBITOR OLAPARIB IN PRECLINICAL MODELS OF UTERINE CANCER Source text for Eikon: Further company coverage:

BRIEF-Aravive Announces Initiation Of Investigator-Sponsored Phase 1/2 Study Of AVB-500 In Combination With Avelumab

* ARAVIVE ANNOUNCES INITIATION OF INVESTIGATOR-SPONSORED PHASE 1/2 STUDY OF AVB-500 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH ADVANCED UROTHELIAL CARCINOMA (COAXIN)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up